ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Relative risk compared with absolute risk for venous thromboembolism by characteristic

Relative risk compared with absolute risk for venous thromboembolism by characteristic
Variable Relative risk compared with nonpregnant women without the risk factor Absolute risk
Nonpregnant, not taking hormones 1.0 VTE: 1 to 5/10,000 woman-years[1]
Pregnancy 4.29 (95% CI 3.49-5.22; p<0.001) compared with nonpregnant women[4]

VTE: 5 to 20/10,000 woman-years[1]

PE: 1/10,000 woman-years
Postpartum 4.29 (95% CI 3.49-5.22; p<0.001) compared with nonpregnant women[4]

VTE: 40 to 65/10,000 woman-years[1]

PE: 16 per 10,000 woman-years
Progestin type RR of VTE:[2,3]  
Non-use versus first-generation (norethindrone COC) users: 3.2 (95% CI 2.0-5.1)  
Non-use versus second-generation (levonorgestrel COC) users: 2.8 (95% CI 2.0-4.1)  
Non-use versus third-generation (desogestrel COC) users: 3.8 (95% CI 2.7-5.4)  
Second versus first generation: 0.9 (95% CI 0.6-1.4)  
Third versus first generation: 1.2 (95% CI 0.8-1.9)  
Third versus second generation: 1.3 (95% CI 1.0-1.8)  
Estrogen dose 20 mcg ethinyl estradiol with levonorgestrel versus non-use: 2.2 (95% CI 1.3-3.6)  
30 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 1.1 (95% CI 0.7-1.7)  
50 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 2.3 (95% CI 1.3-4.2)[2,3]  
Thrombophilias Factor V Leiden: 2.6 no OC, 64.7 first/second generation, 29.6 third generation  
Other heritable thrombophilia: 2.6 no OC, 63.3 first/second generation; 52.5 third generation[4]  
Although drospirenone is not listed, limited data suggest combined oral contraceptive pills containing drospirenone may be associated with a higher relative risk of VTE compared with second-generation (rate ratio 1.65, 95% CI 1.02-2.65) and third-generation (rate ratio 1.43, 95% CI 1.15-1.78) combined oral contraceptive pills.[6]
VTE: venous thromboembolism; CI: confidence interval; PE: pulmonary embolism; RR: relative risk; COC: combined oral contraceptives; OC: oral contraceptives.
References:
  1. Committee on Gynecologic Practice. ACOG Committee Opinion Number 540: Risk of venous thromboembolism among users of drospirenone containing oral contraceptive pills. Obstet Gynecol 2012; 120:1239.
  2. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network metaanalysis. BMJ 2013; 347:f5298.
  3. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; :CD010813.
  4. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.
  5. Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79:28.
  6. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011; 183:E1319.
Reproduced from: Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107:43. Table used with the permission of Elsevier Inc.
Graphic 121107 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟